Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection: A Multi-Arm Multi-Stage Randomized Trial (MAMS) to Evaluate the Effectiveness of Several Specific Treatments in Reducing the Risk of Clinical Worsening or Death in Sub-Saharan Africa (COVERAGE-Africa)

Trial Profile

Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection: A Multi-Arm Multi-Stage Randomized Trial (MAMS) to Evaluate the Effectiveness of Several Specific Treatments in Reducing the Risk of Clinical Worsening or Death in Sub-Saharan Africa (COVERAGE-Africa)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide (Primary) ; Ciclesonide (Primary) ; Fluoxetine (Primary) ; Nitazoxanide (Primary) ; Telmisartan (Primary) ; Paracetamol
  • Indications SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use
  • Acronyms ANTICOV; COVERAGE-A

Most Recent Events

  • 30 Jan 2023 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.
  • 30 Jan 2023 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2023.
  • 05 Jul 2022 Number of treatment arms have been increased from 3 to 4.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top